Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A recent photo of Ajith Kumar has gone viral on social media leaving fans shocked. The reason? Ajith looks like he has lost ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.